Program
HM17321
A development code.
Its studies are mostly in Obesity, led by Hanmi Pharmaceutical.
Furthest: phase 1, since Oct 16, 20251 company-led study, 1 open or runningNext primary completion: Mar 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hanmi Pharmaceutical | 11 open or running | phase 1since Oct 16, 2025 | Oct 16, 2025 | Mar 2027phase 1 · NCT07219589 |
- Named in hoffmann la roche’s own pipeline as
RG7985 UCN-2 analog (Hanmi)
, phase 1, as of Oct 22, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 16, 2025First study: phase 1 study in ObesityFirst studyNCT07219589 · 90 planned · United States
Ahead
- Mar 2027Primary completion: phase 1 study in ObesityNCT07219589
TargetBeta
UCN2 →read by rule
“This is a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321, a urocortine 2 (UCN2) analog, administered by subcutaneous (SC) injection in healthy and obes…”study text, by rule · the study
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07219589Obesity · United States | 1 | Recruiting | Mar 2027 | 90 |
How it is read
Names in the registry
- “HM17321”, 1 entry
Codes read as this program: HM17321.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.